0001104659-13-001472.txt : 20130214 0001104659-13-001472.hdr.sgml : 20130214 20130109160613 ACCESSION NUMBER: 0001104659-13-001472 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494-2725 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

 

CELLDEX THERAPEUTICS, INC.

119 Fourth Avenue

Needham, Massachusetts 02494

 

January 9, 2013

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C.  20549

 

Re:          Celldex Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-185647)

 

Ladies and Gentlemen:

 

In connection with the above-captioned registration statement, and pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended (the “Act”), the Company hereby requests that the effective date of the above-mentioned registration statement be accelerated to 5:00 p.m. (New York time) on Wednesday, January 16, 2013, or as soon thereafter as practicable.

 

The Company hereby acknowledges that:

 

·                  should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

·                  the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

·                  the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

[signature page follows]

 


 

 

 

Very truly yours,

 

 

 

 

 

CELLDEX THERAPEUTICS, INC.

 

 

 

 

 

 

 

 

By:

/s/ Anthony S. Marucci

 

 

 

Anthony S. Marucci

 

 

 

President and Chief Executive Officer